Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Core Insights - Supernus Pharmaceuticals achieved record revenues of $719 million in 2025, driven by a 40% revenue increase from four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now account for 76% of total revenues [4] - The company successfully integrated the acquisition of Sage Therapeutics, adding ZURZUVAE to its portfolio and establishing a presence in the women's health and postpartum depression markets [4] - Projected total revenues for 2026 are estimated to be between $840 million and $870 million, with ONAPGO expected to contribute $45 million to $70 million as supply stabilizes [4] Strategic Performance and Operational Context - The company managed ONAPGO supply constraints by prioritizing existing patient maintenance and preparing to resume new patient initiations in early 2026 [4] - Qelbree's fourth-quarter net sales lagged behind prescription growth due to an unexpected $4 million PBM bill for the full year of 2025 [4] - The company maintains a disciplined R&D approach, retaining high-potential Sage assets for internal development while seeking external partnerships for early-stage pipeline candidates [4] 2026 Outlook and Strategic Priorities - The strategic focus for 2026 includes clearing the ONAPGO patient backlog and transitioning to a second manufacturing supplier by 2027 to ensure long-term capacity [4] - The M&A strategy is focused on revenue-generating assets or late-stage pipeline candidates that could launch between 2027 and 2031 [4] - Clinical timelines for SPN-820 (depression) and SPN-817 (epilepsy) target top-line data readouts in 2027, with SPN-820 expected to recruit faster due to the indication type [4] Financial Performance - The company recorded $73 million in acquisition-related costs and $50 million in incremental operating costs associated with the Sage Therapeutics transaction in 2025 [4] - A GAAP operating loss of $62.3 million was reported for 2025, primarily due to one-time acquisition expenses and higher intangible asset amortization for new products [4] Market Opportunities - A 700-patient queue for ONAPGO awaiting benefit verification represents a significant near-term revenue conversion opportunity as supply resumes [6] - High demand for ONAPGO exists, but the conversion of 1,800 enrollment forms to active patients is subject to typical specialty pharmacy attrition and reimbursement hurdles [6]